<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38431" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>CNS Lymphoma (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mullangi</surname>
            <given-names>Sanjana</given-names>
          </name>
          <aff>Hillcrest Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lekkala</surname>
            <given-names>Manidhar Reddy</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjana Mullangi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38431.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma. It is a rare entity and involves the central nervous system (CNS), which includes the brain, spinal cord, cerebrospinal fluid (CSF), leptomeninges, and eyes and has no evidence of any disease outside the CNS. Unlike the other primary CNS tumors, they respond well to chemotherapy and radiation but have inferior survival compared to other lymphomas outside the CNS.</p>
      </sec>
      <sec id="article-38431.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of PCNSL is unclear and is largely undefined, similar to other types of lymphoma.<xref ref-type="bibr" rid="article-38431.r1">[1]</xref><xref ref-type="bibr" rid="article-38431.r2">[2]</xref>&#x000a0;The most common cause for PCNSL is acquired or congenital immunodeficiency. Patients with congenital immunodeficiency such as&#x000a0;the severe combined or common immunodeficiency, X-linked lymphoproliferative disorders, Wiskott-Aldrich syndrome, and ataxia-telangiectasia have a 4 percent lifetime risk of developing PCNSL.</p>
        <p>Acquired causes like human immunodeficiency virus<italic toggle="yes">&#x000a0;(</italic>HIV) infection, chronic immunosuppression, and organ transplant are other commonly known etiologies. PCNSL is an&#x000a0;acquired immunodeficiency syndrome (AIDS)-defining event and is associated with low CD-4 counts &#x0003c; 50 cells/microliter. AIDS-related PCNSL shares an association with Epstein-Barr virus (EBV) 100 percent of the time.<xref ref-type="bibr" rid="article-38431.r3">[3]</xref>&#x000a0;PCNSL also can develop in immunocompetent patients and sometimes have been associated with an autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, or sarcoidosis, etc.<xref ref-type="bibr" rid="article-38431.r2">[2]</xref></p>
      </sec>
      <sec id="article-38431.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PCNSLs are rare and represent only about 4-6 percent of extra-nodal lymphomas.<xref ref-type="bibr" rid="article-38431.r4">[4]</xref>&#x000a0;About 4 percent of intracranial neoplasms are PCNSL. The incidence of PCNSL increased from the 1960s to the 1990s due to the HIV pandemic and then declined.<xref ref-type="bibr" rid="article-38431.r5">[5]</xref><xref ref-type="bibr" rid="article-38431.r6">[6]</xref>&#x000a0;</p>
        <p>Approximately 1500 new cases of PCNSL are diagnosed in the United States every year. In the last 10 years, there has been a rising incidence in patients older than 65 years, and the incidence is 4.3 cases per million population in patients 70&#x000a0;to 79 years.<xref ref-type="bibr" rid="article-38431.r7">[7]</xref>&#x000a0;Men and women are equally affected, and the median age of diagnosis is in the fifth decade.<xref ref-type="bibr" rid="article-38431.r4">[4]</xref></p>
      </sec>
      <sec id="article-38431.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In PCNSL cohorts, recurrent mutations in the MYD88 and CD79B genes that affect the B-cell signaling pathways with its downstream target NFkB is believed to play a role in the pathogenesis.<xref ref-type="bibr" rid="article-38431.r8">[8]</xref><xref ref-type="bibr" rid="article-38431.r9">[9]</xref><xref ref-type="bibr" rid="article-38431.r10">[10]</xref><xref ref-type="bibr" rid="article-38431.r11">[11]</xref>&#x000a0;It is unclear regarding the origin of the cells of primary CNS lymphoma, whether they first arise in the CNS or rather arise systemically and later travel to the CNS.<xref ref-type="bibr" rid="article-38431.r12">[12]</xref></p>
      </sec>
      <sec id="article-38431.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Most PCNSLs are diffuse large B cell lymphoma (DLBCL), which constitutes about 95 percent of cases. Neoplastic B lymphocytes express pan-B cell markers and markers of germinal center and late germinal cell B cells. Less common histologies include Burkitt, T-cell PCNSL, lymphoblastic, and intraparenchymal marginal zone lymphoma.<xref ref-type="bibr" rid="article-38431.r13">[13]</xref>&#x000a0;The majority of the PCNSL tumors express the pan B cell markers CD19, CD20, CD22, and CD79a and more than half of them express both the BCL6 and MUM1. The tumor cells are highly infiltrative, and cells display perivascular growth, associated with a worse prognosis.<xref ref-type="bibr" rid="article-38431.r12">[12]</xref></p>
      </sec>
      <sec id="article-38431.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common symptoms, which usually span weeks to few months, are focal deficits, change in personality, seizures, confusion, lethargy, and high intracranial pressure symptoms like headaches, nausea, vomiting, papilledema.<xref ref-type="bibr" rid="article-38431.r14">[14]</xref>&#x000a0;Typical B symptoms are rare.<xref ref-type="bibr" rid="article-38431.r15">[15]</xref>&#x000a0;Intraocular involvement is noted in about 10&#x000a0;to 20 percent of patients. Thus, some patients develop ocular symptoms like floaters, blurry vision, and diminished visual acuity and vision fields. A leptomeningeal involvement is noted in about 40 percent of the patients and along with the previously described symptoms, patients can also have meningismus and cervical/lumbar radiculopathies. Cranial nerve deficits can occur due to the involvement of the brain stem or isolated cranial nerve roots. Primary spinal involvement is seen in &#x0003c;1 percent of the patients and causes progressive myelopathy and back pain.</p>
      </sec>
      <sec id="article-38431.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In addition to a detailed history and physical, the evaluation of the patients suspected to have a PCNSL should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Imaging of the CNS, ideally with a magnetic resonance imaging (MRI) and gadolinium contrast.</p>
          </list-item>
          <list-item>
            <p>CSF analysis</p>
          </list-item>
          <list-item>
            <p>An eye exam with a slit lamp</p>
          </list-item>
          <list-item>
            <p>Testicular exam and ultrasound in male patients.</p>
          </list-item>
        </list>
        <p>In immunocompetent patients with newly diagnosed PCNSL, &#x0003e;60 percent of the patients have solitary lesions, and about 35 percent have multifocal lesions. Cerebral hemispheric involvement is the most common, followed by the thalamus, basal ganglia, corpus callosum, and cerebellum.<xref ref-type="bibr" rid="article-38431.r16">[16]</xref>&#x000a0;Lesions are usually iso-dense to hypo-dense on T2-weighted MRI, with variable edema and homogenous and strong enhancement.<xref ref-type="bibr" rid="article-38431.r16">[16]</xref>&#x000a0;</p>
        <p>Computed tomography (CT) of the head with contrast is an alternative in patients who have MRI contraindications. The definitive diagnosis requires a pathologic confirmation with a biopsy. The most commonly used biopsy procedure is the use of stereotactic brain biopsy; rarely, some patients have a partial or total resection. The morbidity related to the stereotactic biopsy is very low and permits rapid detection. The safety of CSF analysis should be considered in patients suspected of having increased intracranial pressure. CSF analysis should include cell count, protein levels, glucose levels along with cytology, and flow cytometry analysis. Along with the slit lamp examination of the eyes, a CT scan of the chest, abdomen, and pelvis should be obtained for documentation of any other organ involvement or lymphadenopathy. A bone marrow biopsy is also recommended to complete a full staging workup. These systemic staging procedures are important as about 10 percent of patients who are presumed to have PCNSL, have an extra CNS involvement.<xref ref-type="bibr" rid="article-38431.r17">[17]</xref>&#x000a0;</p>
        <p>Blood work with screening HIV, hepatitis B, and C serology, lactate dehydrogenase, comprehensive metabolic panel, liver function tests, and complete blood counts are recommended.<xref ref-type="bibr" rid="article-38431.r18">[18]</xref>&#x000a0;Corticosteroids are lymphocytotoxic and can obscure pathologic diagnosis, and it is recommended that, if possible, empiric administration of steroids be delayed until the diagnosis is established.<xref ref-type="bibr" rid="article-38431.r19">[19]</xref></p>
      </sec>
      <sec id="article-38431.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>PCNSL is highly sensitive to radiation and some chemotherapy agents, which is in contrast to the other primary brain-related tumors. The role of surgery is limited. Antimetabolites such as methotrexate (MTX) given at high doses constitutes the backbone for the treatment of PCNSL. Standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, the backbone for extra-CNS DLBCL exhibits negligible activity in PCNSL and/or has higher toxicity in combination with high dose MTX (HD-MTX) without improved outcomes.<xref ref-type="bibr" rid="article-38431.r20">[20]</xref><xref ref-type="bibr" rid="article-38431.r21">[21]</xref></p>
        <p>Due to the high sensitivity of the PCNSL to radiation, patients initially were treated with whole-brain radiation therapy (WBRT). The use of WBRT as a first-line treatment is decreasing as chemotherapy-based regimens are optimized, and no significant benefit is noted with added WBRT, and it is associated with significant neurotoxicity.<xref ref-type="bibr" rid="article-38431.r22">[22]</xref><xref ref-type="bibr" rid="article-38431.r23">[23]</xref></p>
        <p>It is proven in multiple trials, induction therapy with the combination of HD-MTX with other agents showed improved complete response (CR) compared to single-agent MTX.<xref ref-type="bibr" rid="article-38431.r24">[24]</xref><xref ref-type="bibr" rid="article-38431.r25">[25]</xref><xref ref-type="bibr" rid="article-38431.r26">[26]</xref>&#x000a0;Examples of induction therapy are HD-MTX plus cytarabine or HD-MTX with temozolomide or HD-MTX with procarbazine plus vincristine. Rituximab is added to the induction regimens in CD20 positive PCNSL, which constitutes the majority and is fairly well tolerated. The goal of the induction regimen is CR. The choice of induction therapy depends on institutional experience, comorbidities, and organ function. In older adults, the treatment decisions are individualized, and a single agent HD-MTX is sometimes reasonable. The number of cycles of HD-MTX is inconclusive, but patients may require a median number of 6-8 cycles for achieving CR, and in clinical practice, it is not unusual to receive 10 to 12 cycles.</p>
        <p>MTX doses greater than 3.5 gm/m2 yield tumoricidal levels in the CSF and the brain parenchyma and doses as high as 8 gm/m2 were used in the clinical trial but required dose reductions secondary to side effects.<xref ref-type="bibr" rid="article-38431.r27">[27]</xref></p>
        <p>MTX at low doses is not nephrotoxic. At high doses, as used in PCNSL, MTX can precipitate in the tubules of the kidney and cause direct damage, the risk of which increases in the presence of acidic urine. Even though the MTX related kidney injury is reversible, the major risk is the decreased clearance of MTX after the high dose administration leading to increased systemic toxicity. This likelihood of renal injury can be minimized with aggressive hydration and alkalinization of urine. Leucovorin rescue is initiated within 24 to 36 hours of starting HD-MTX until the plasma level of MTX is less than 0.05 to 0.1 microliter.<xref ref-type="bibr" rid="article-38431.r28">[28]</xref>&#x000a0;As MTX is not lipophilic, it can accumulate at high concentrations in third space fluid collections like pleural effusion and ascites and leak back into circulation long after the initial dose and cause significant toxicity. These collections should be drained prior to MTX administration.&#x000a0;</p>
        <p>In patients who achieved CR, at least half of them will relapse within five years. High dose chemotherapy with autologous hematopoietic stem cell transplantation (HCT) and whole-brain radiation therapy (WBRT) are the two consolidation approaches being considered. A growing number of prospective studies are researching these approaches, and overall evidence supports efficacy to be similar to both approaches, but there is higher neurotoxicity with WBRT.<xref ref-type="bibr" rid="article-38431.r29">[29]</xref><xref ref-type="bibr" rid="article-38431.r30">[30]</xref>&#x000a0;Due to high toxicities associated with high dose chemotherapy with HCT, other non-myeloablative regimens are being tested. The most common non-myeloablative regimens consist of high dose cytarabine with or without etoposide.<xref ref-type="bibr" rid="article-38431.r25">[25]</xref><xref ref-type="bibr" rid="article-38431.r31">[31]</xref>&#x000a0;</p>
        <p>
<bold>Surveillance</bold>
</p>
        <p>After completion of initial therapy, patients are followed for any concern for relapse and long-term toxicities. Patients are evaluated with an MRI with gadolinium enhancement. The majority of relapses occur within 5 years after completion of the therapy. It is recommended to follow up with patients every&#x000a0;three months during the first 2 years and every 6 months for the next 3 years.</p>
        <p>
<bold>Relapse/Refractory Disease</bold>
</p>
        <p>Treatment of relapsed and refractory disease is limited and therapeutic approaches to consider are retreatment with an MTX-based regimen, alternative chemotherapy agents such as pemetrexed, temozolomide, and ifosfamide,&#x000a0;and high dose chemotherapy with HCT, and WBRT in previously non radiated patients. Other options include the use of other agents like lenalidomide and ibrutinib.<xref ref-type="bibr" rid="article-38431.r32">[32]</xref><xref ref-type="bibr" rid="article-38431.r33">[33]</xref><xref ref-type="bibr" rid="article-38431.r34">[34]</xref><xref ref-type="bibr" rid="article-38431.r35">[35]</xref></p>
      </sec>
      <sec id="article-38431.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The main differential diagnoses, requiring brain biopsy for definitive diagnosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gliomas</p>
          </list-item>
          <list-item>
            <p>Metastases</p>
          </list-item>
          <list-item>
            <p>Toxoplasmosis</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Histiocytic lesions</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal leukoencephalopathy</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Inflammatory disorders like vasculitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38431.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Two scoring systems are used for predicting outcomes and stratifying patients with PCNSL.</p>
        <list list-type="bullet">
          <list-item>
            <p>International Extranodal Lymphoma Study Group (IELSG) score<xref ref-type="bibr" rid="article-38431.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score<xref ref-type="bibr" rid="article-38431.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>The IELSG score includes the use of 5 parameters to determine prognosis<xref ref-type="bibr" rid="article-38431.r36">[36]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Eastern Cooperative Oncology Group (ECOG) performance score</p>
          </list-item>
          <list-item>
            <p>Age</p>
          </list-item>
          <list-item>
            <p>CSF protein concentration</p>
          </list-item>
          <list-item>
            <p>Serum lactate dehydrogenase (LDH) serum level</p>
          </list-item>
          <list-item>
            <p>Deep brain involvement</p>
          </list-item>
        </list>
        <p>The two-year survival rates depending on the presence of the above risk factors are:</p>
        <list list-type="order">
          <list-item>
            <p>0 to 1 adverse factor &#x02013; 80% survival rate</p>
          </list-item>
          <list-item>
            <p>2 to 3 adverse factors - 48% survival rate</p>
          </list-item>
          <list-item>
            <p>4 to 5 adverse factors - 15% survival rate</p>
          </list-item>
        </list>
        <p>Three prognostic groups are defined by the MSKCC score using Karnofsky performance status (KPS) and age<xref ref-type="bibr" rid="article-38431.r37">[37]</xref>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Age &#x02264;50 &#x02013; median overall survival 8.5 years</p>
          </list-item>
          <list-item>
            <p>Age &#x0003e;50 and KPS &#x02265;70 &#x02013; median overall survival 3.2 years</p>
          </list-item>
          <list-item>
            <p>Age &#x0003e;50 and KPS &#x0003c;70 &#x02013; median overall survival 1.1 years</p>
          </list-item>
        </list>
        <p>The median overall survival has increased in patients with PCNSL in the United States from 12 months in the 1960s to 26 months in the 2010s.<xref ref-type="bibr" rid="article-38431.r7">[7]</xref>&#x000a0;Most of the benefit is seen in patients younger than 70 years of age. The prognosis of refractory or relapsed PCNSL is very poor and survival is less than 6 months.</p>
      </sec>
      <sec id="article-38431.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications related to the PCNSL are usually neurological and are also related to the treatment. Some of the common complications noted include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Cognitive dysfunction</p>
          </list-item>
          <list-item>
            <p>Hemorrhage into the brain</p>
          </list-item>
          <list-item>
            <p>Obstructive hydrocephalus</p>
          </list-item>
          <list-item>
            <p>Spinal cord compression</p>
          </list-item>
          <list-item>
            <p>Complications related to the treatment,&#x000a0;including acute kidney injury, increased infections, cognitive impairment, decreased memory, cardiotoxicity, etc.</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38431.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and their caretakers should be educated on the diagnosis of the PCNSL, especially regarding the disease process and potential pitfalls. Education should be given regarding the treatment considerations and side effects associated with the various therapies. Adequate hydration during HD-MTX therapy is important, as MTX can precipitate in renal tubules and cause kidney injury. Education is also given regarding the avoidance of particular medications that can interact with chemotherapy. Patients should be educated regarding approaching the treatment team for any concerns that arise during the treatment.</p>
      </sec>
      <sec id="article-38431.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of PCNSL is complex and needs an interprofessional team approach involving neurologists, medical oncologists, radiation oncologists, hematopathologists, radiologists, ophthalmologists, neurosurgeons as well as other allied health professionals. Medical oncology and radiation oncology play a crucial role in the management of PCNSL.&#x000a0;It is recommended that these patients are discussed in an&#x000a0;interprofessional tumor board for a consensus treatment plan. This approach will facilitate optimal patient care, individualized treatment decisions, and also improve enrollment in the clinical trials. Nursing administers the chemotherapy and pharmacists specialized in oncology will verify agent selection, dose as well as drug interactions. The nurses should alert the treating clinician of any concerns or adverse reactions.</p>
        <p>CNS lymphoma has a guarded prognosis, and treatment decisions should be made involving the patient, family, and the healthcare team. The involvement of the palliative care team in the early phases of diagnosis may benefit these patients. Extensive communication with the patient and families improve the outcomes of patients with PCNSL. [Level 4]</p>
      </sec>
      <sec id="article-38431.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38431&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38431">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38431/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38431">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38431.s15">
        <title>References</title>
        <ref id="article-38431.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schabet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of primary CNS lymphoma.</article-title>
            <source>J Neurooncol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-201</page-range>
            <pub-id pub-id-type="pmid">10563423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhagavathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>132</volume>
            <issue>11</issue>
            <fpage>1830</fpage>
            <page-range>1830-4</page-range>
            <pub-id pub-id-type="pmid">18976024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cingolani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gastaldi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fassone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pierconti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giancola</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ammassari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazzone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pescarmona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larocca</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Antinori</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas.</article-title>
            <source>J Clin Oncol</source>
            <year>2000</year>
            <month>Oct</month>
            <day>01</day>
            <volume>18</volume>
            <issue>19</issue>
            <fpage>3325</fpage>
            <page-range>3325-30</page-range>
            <pub-id pub-id-type="pmid">11013271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Koshy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dolecek</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.</article-title>
            <source>Br J Cancer</source>
            <year>2011</year>
            <month>Oct</month>
            <day>25</day>
            <volume>105</volume>
            <issue>9</issue>
            <fpage>1414</fpage>
            <page-range>1414-8</page-range>
            <pub-id pub-id-type="pmid">21915121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Propp</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.</article-title>
            <source>Neuro Oncol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-37</page-range>
            <pub-id pub-id-type="pmid">16443945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haldorsen</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Krossnes</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Aarseth</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Scheie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johannesen</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Mella</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Espeland</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.</article-title>
            <source>Cancer</source>
            <year>2007</year>
            <month>Oct</month>
            <day>15</day>
            <volume>110</volume>
            <issue>8</issue>
            <fpage>1803</fpage>
            <page-range>1803-14</page-range>
            <pub-id pub-id-type="pmid">17721992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendez</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ostrom</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kruchko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Barnholtz-Sloan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Grommes</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.</article-title>
            <source>Neuro Oncol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>09</day>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>687</fpage>
            <page-range>687-694</page-range>
            <pub-id pub-id-type="pmid">29036697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boisselier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Labreche</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Polivka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jouvet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Figarella-Branger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miquel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eimer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mokhtari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daveau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mutational analysis of primary central nervous system lymphoma.</article-title>
            <source>Oncotarget</source>
            <year>2014</year>
            <month>Jul</month>
            <day>15</day>
            <volume>5</volume>
            <issue>13</issue>
            <fpage>5065</fpage>
            <page-range>5065-75</page-range>
            <pub-id pub-id-type="pmid">24970810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tateishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shuto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyakita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kocialkowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sasayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maehara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ushijima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawahara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ichimura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.</article-title>
            <source>Neuropathol Appl Neurobiol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-90</page-range>
            <pub-id pub-id-type="pmid">26111727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vater</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Montesinos-Rongen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlesner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Purschke</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sprute</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mettenmeyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nazzal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gutwein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buchhalter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Wiestler</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Eils</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deckert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.</article-title>
            <source>Leukemia</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>677</fpage>
            <page-range>677-85</page-range>
            <pub-id pub-id-type="pmid">25189415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapuy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roemer</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dunford</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Meredith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thorner</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jordanova</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Feuerhake</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ducar</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Illerhaus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gusenleitner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Linden</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Homer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aono</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinkus</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Ligon</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ligon</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>van Hummelen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Golub</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Getz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodig</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Targetable genetic features of primary testicular and primary central nervous system lymphomas.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Feb</month>
            <day>18</day>
            <volume>127</volume>
            <issue>7</issue>
            <fpage>869</fpage>
            <page-range>869-81</page-range>
            <pub-id pub-id-type="pmid">26702065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Advances in Pathobiology of Primary Central Nervous System Lymphoma.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2017</year>
            <month>Aug</month>
            <day>20</day>
            <volume>130</volume>
            <issue>16</issue>
            <fpage>1973</fpage>
            <page-range>1973-1979</page-range>
            <pub-id pub-id-type="pmid">28776551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenkier</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Poortmans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Neuwelt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Apr</month>
            <day>01</day>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>2233</fpage>
            <page-range>2233-9</page-range>
            <pub-id pub-id-type="pmid">15800313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bataille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delwail</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Menet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vandermarcq</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ingrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lapierre</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Primary intracerebral malignant lymphoma: report of 248 cases.</article-title>
            <source>J Neurosurg</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>261</fpage>
            <page-range>261-6</page-range>
            <pub-id pub-id-type="pmid">10659013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calderoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tirelli</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pivnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aondio</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ferrarese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borisch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chassagne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iuzzolino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pedrinis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Motta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jouvet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>A multicenter study of treatment of primary CNS lymphoma.</article-title>
            <source>Neurology</source>
            <year>2002</year>
            <month>May</month>
            <day>28</day>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1513</fpage>
            <page-range>1513-20</page-range>
            <pub-id pub-id-type="pmid">12034789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;ker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>N&#x000e4;gele</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Korfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heckl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.</article-title>
            <source>J Neurooncol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-77</page-range>
            <pub-id pub-id-type="pmid">15925998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zoldan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Terreni</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion.</article-title>
            <source>Cancer</source>
            <year>1996</year>
            <month>Mar</month>
            <day>01</day>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>827</fpage>
            <page-range>827-33</page-range>
            <pub-id pub-id-type="pmid">8608471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Batchelor</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pulczynski</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Korfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Neuwelt</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shenkier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van den Bent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Poortmans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <collab>International Primary CNS Lymphoma Collaborative Group</collab>
            </person-group>
            <article-title>Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Aug</month>
            <day>01</day>
            <volume>23</volume>
            <issue>22</issue>
            <fpage>5034</fpage>
            <page-range>5034-43</page-range>
            <pub-id pub-id-type="pmid">15955902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Glucocorticoid treatment of primary CNS lymphoma.</article-title>
            <source>J Neurooncol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-9</page-range>
            <pub-id pub-id-type="pmid">10563429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mead</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bleehen</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bullimore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shirley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rampling</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Trevor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ironside</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Brada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whaley</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Stenning</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Sep</month>
            <day>15</day>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>1359</fpage>
            <page-range>1359-70</page-range>
            <pub-id pub-id-type="pmid">11002232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shustik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Cher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).</article-title>
            <source>J Neurooncol</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-65</page-range>
            <pub-id pub-id-type="pmid">8943101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Korfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Griesinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000f6;th</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>von Toll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hundsberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mergenthaler</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Leith&#x000e4;user</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birnbaum</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Plasswilm</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>N&#x000e4;gele</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pietsch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>1036</fpage>
            <page-range>1036-47</page-range>
            <pub-id pub-id-type="pmid">20970380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000f6;hle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Griesinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000f6;th</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hundsberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mergenthaler</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Junghan&#x000df;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birnbaum</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pietsch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Mar</month>
            <day>24</day>
            <volume>84</volume>
            <issue>12</issue>
            <fpage>1242</fpage>
            <page-range>1242-8</page-range>
            <pub-id pub-id-type="pmid">25716362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foppoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pangalis</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Frezzato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabras</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corazzelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ilariucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stelitano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vallisa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zoppegno</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aondio</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Avvisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Balzarotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Fajardo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rigacci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Uhlmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Picozzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vezzulli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caligaris-Cappio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <collab>International Extranodal Lymphoma Study Group (IELSG)</collab>
            </person-group>
            <article-title>High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Oct</month>
            <day>31</day>
            <volume>374</volume>
            <issue>9700</issue>
            <fpage>1512</fpage>
            <page-range>1512-20</page-range>
            <pub-id pub-id-type="pmid">19767089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubenstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hsi</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>31</volume>
            <issue>25</issue>
            <fpage>3061</fpage>
            <page-range>3061-8</page-range>
            <pub-id pub-id-type="pmid">23569323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raizer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <day>01</day>
            <volume>31</volume>
            <issue>31</issue>
            <fpage>3971</fpage>
            <page-range>3971-9</page-range>
            <pub-id pub-id-type="pmid">24101038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batchelor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Priet</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Mar</month>
            <day>15</day>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1044</fpage>
            <page-range>1044-9</page-range>
            <pub-id pub-id-type="pmid">12637469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Buddington</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Preventing and Managing Toxicities of High-Dose Methotrexate.</article-title>
            <source>Oncologist</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>1471</fpage>
            <page-range>1471-1482</page-range>
            <pub-id pub-id-type="pmid">27496039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Cwynarski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pulczynski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Schorb</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>La Ros&#x000e9;e</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Binder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Minacapelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Falautano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilariucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hemmaway</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linton</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pukrop</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>S&#x000f8;nderskov G&#x000f8;rl&#x000f8;v</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balzarotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Orsucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Schmoll</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pfreundschuh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabras</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Angrilli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deckert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Politi</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Finke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Illerhaus</surname>
                <given-names>G</given-names>
              </name>
              <collab>International Extranodal Lymphoma Study Group (IELSG)</collab>
            </person-group>
            <article-title>Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.</article-title>
            <source>Lancet Haematol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>e510</fpage>
            <page-range>e510-e523</page-range>
            <pub-id pub-id-type="pmid">29054815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taillandier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dureau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laadhari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Molu&#x000e7;on-Chabrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soubeyran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thyss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delwail</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanhes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cornillon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garidi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Delmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanguy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Al Jijakli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bourquard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moles</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Chauchet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gastinne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Constans</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moisson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacomblez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martin-Duverneuil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Delgadillo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turbiez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Feuvret</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <collab>Intergroupe GOELAMS&#x02013;ANOCEF and the LOC Network for CNS Lymphoma</collab>
            </person-group>
            <article-title>Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>823</fpage>
            <page-range>823-833</page-range>
            <pub-id pub-id-type="pmid">30785830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Raizer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LaRocca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Oct</month>
            <day>20</day>
            <volume>25</volume>
            <issue>30</issue>
            <fpage>4730</fpage>
            <page-range>4730-5</page-range>
            <pub-id pub-id-type="pmid">17947720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Martin-Duverneuil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mokhtari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Jan</month>
            <day>20</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-6</page-range>
            <pub-id pub-id-type="pmid">25527263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghesquieres</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chevrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laadhari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Molu&#x000e7;on-Chabrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beauchesne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Garff-Tavernier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savignoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turbiez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soumelis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)&#x02020;.</article-title>
            <source>Ann Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-628</page-range>
            <pub-id pub-id-type="pmid">30698644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grommes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palaskas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schartz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Codega</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Rohle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabar</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Gavrilovic</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Kaley</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pentsova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tsyvkin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palomba</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hamlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lallana</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hatzoglou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Huse</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Graeber</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Mellinghoff</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.</article-title>
            <source>Cancer Discov</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>1018</fpage>
            <page-range>1018-1029</page-range>
            <pub-id pub-id-type="pmid">28619981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soussain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blonski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leclercq</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Houillier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rezai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bijou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Houot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barrie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molu&#x000e7;on-Chabrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lelez</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Clavert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coisy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leruez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Daniau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ertault de la Bretonni&#x000e8;re</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Yamani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghesqui&#x000e8;res</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.</article-title>
            <source>Eur J Cancer</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>117</volume>
            <fpage>121</fpage>
            <page-range>121-130</page-range>
            <pub-id pub-id-type="pmid">31279304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calderoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vavassori</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devizzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ponzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borisch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tinguely</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cerati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orvieto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chevreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dell'Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Jan</month>
            <day>15</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>266</fpage>
            <page-range>266-72</page-range>
            <pub-id pub-id-type="pmid">12525518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38431.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrey</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Ben-Porat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berkey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leibel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Dec</month>
            <day>20</day>
            <volume>24</volume>
            <issue>36</issue>
            <fpage>5711</fpage>
            <page-range>5711-5</page-range>
            <pub-id pub-id-type="pmid">17116938</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
